14 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new
7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global
Investors snapped up shares in biotech company Oxford Nanopore after its IPO this morning, with the shares soaring 45 per cent.
MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, notes the recent Government statement regarding measures to simplify international travel.
Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the
MyHealthChecked plc (AIM: MHC), the consumer home-testing healthcare company, announces that Peter Dines, Non-executive Director, has today stepped down from the Board. Peter is Chief Operating Officer at Mercia Asset
MyHealthChecked approved as a PCR and sequencing provider for day two and day eight coronavirus testing for international arrivals
Braveheart is pleased to provide an update concerning the development of a COVID-19 test that Paraytec Limited is conducting with the University of Sheffield.
N4P has provided an update on its Nuvec® optimisation programme and proof of concept work involving COVID-19. Interestingly, delays imposed by the Pandemic lockdown presented an opportunity for the Group
Braveheart is pleased to provide an update concerning the development of a COVID-19 test with the University of Sheffield.
Further to the Company’s announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is
